Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364531 | 1.00 | ADRA2C (0.44) | ADRA2CCYP19A1LMNAPKMKMT2A | |
| SCHEMBL10978037 | 0.92 | CYP19A1 (0.46) | ADRA2CCYP19A1LMNAPKMKMT2A | |
| SCHEMBL10364855 | 0.86 | CYP19A1 (0.43) | ADRA2CCYP19A1LMNAPKMKMT2A | |
| Alcohol SCHEMBL27859648 | 0.84 | CYP3A4 (0.39) | ADRA2CCYP19A1LMNAPKMKMT2A | |
| Penconazole SCHEMBL29416459 | 0.84 | CYP19A1 (0.41) | ADRA2CCYP19A1LMNAPKMKMT2A | |
| SCHEMBL10833443 | 0.84 | CYP19A1 (0.41) | ADRA2CCYP19A1LMNAPKMKMT2A | |
| Penconazole SCHEMBL24791 | 0.84 | CYP19A1 (0.41) | ADRA2CCYP19A1LMNAPKMKMT2A | |
| SCHEMBL10832681 | 0.84 | CYP3A4 (0.45) | ADRA2CCYP19A1LMNAPKMKMT2A | |
| Penconazole SCHEMBL3003031 | 0.84 | CYP19A1 (0.41) | ADRA2CCYP19A1LMNAPKMKMT2A | |
| Penconazole SCHEMBL8050480 | 0.84 | CYP19A1 (0.41) | ADRA2CCYP19A1LMNAPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| EP-3230268-B1 | PROCESS FOR THE PREPARATION OF TETRACONAZOLE | ISAGRO SPA (IT) | 2018-12-12 | — | — | EP | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-9884829-B2 | Process for the preparation of tetraconazole | ISAGRO S.P.A. (IT) | 2018-02-06 | — | — | US | claimed |
| US-20170327473-A1 | PROCESS FOR THE PREPARATION OF TETRACONAZOLE | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2017-11-16 | — | — | US | claimed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240210288-A1 | Representative Diagnostics | VENTANA MED SYST INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| US-11959838-B2 | Representative diagnostics | VENTANA MEDICAL SYSTEMS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3230268-A1 | PROCESS FOR THE PREPARATION OF TETRACONAZOLE | ISAGRO S.p.A. (IT) | 2017-10-18 | — | — | EP | disclosed |
| WO-2017079763-A1 | REPRESENTATIVE DIAGNOSTICS | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| WO-2016092573-A1 | PROCESS FOR THE PREPARATION OF TETRACONAZOLE | ISAGRO S.P.A. (IT) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092573-A1 | PROCESS FOR THE PREPARATION OF TETRACONAZOLE | ISAGRO S.P.A. (IT) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092573-A1 | PROCESS FOR THE PREPARATION OF TETRACONAZOLE | ISAGRO S.P.A. (IT) | 2016-06-16 | — | — | WO | disclosed |
| US-5081141-A | 1,2,4-triazole derivatives as fungicides | MONTEDISON S.P.A. (IT) | 1992-01-14 | — | — | US | disclosed |
| EP-0234242-B1 | FUNGICIDAL AZOLYL-DERIVATIVES | MONTEDIPE S.r.l. (IT) | 1991-08-07 | — | — | EP | disclosed |
| EP-0234242-A2 | Fungicidal azolyl-derivatives | MONTEDIPE S.r.l. (IT) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | ADRA2C 2576/4885CYP19A1 4556/4885LMNA 3363/4885 |
| US-20170327473-A1 | PROCESS FOR THE PREPARATION OF TETRACONAZOLE | CYP51A1, CYP3A4, CYP3A43 | ADRA2C 460/4885CYP19A1 389/4885LMNA 2520/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | ADRA2C 2576/4885CYP19A1 4556/4885LMNA 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.